The angiotensin-converting enzyme (ACE) inhibitor trandolapril, a non-sulfhydryl prodrug which is hydrolysed into trandolaprilat, was studied in 322 hypertensives of African-American descent using a doubleblind, randomised, placebo-controlled, parallel study design. Following 6 weeks of double-blind treatment with placebo or 0.25 to 16 mg/day trandolapril, an analysis of drug effect on trough blood pressure (BP) stratified by age, gender, weight, pre-treatment plasma renin activity, and trandolaprilat concentration was performed. Two mg was the lowest effective trandolapril dose, whereas doses above 4 mg did not significantly reduce
Introduction
Hypertensives of African-American descent manifest hypertensive disease earlier and more frequently than their non-black counterparts. [1] [2] [3] [4] They also tend to have a lower renin, more salt sensitive physiology and a tendency toward subtle volume expansion, coupled with more systemic and intrarenal vasoconstriction. [5] [6] [7] [8] [9] This pathophysiological background may explain why African-American hypertensives tend to be more resistant to lower doses of commonly used anti-hypertensive medications which target the renin-angiotensin system and have a different efficacy response to some antihypertensive drugs compared to non-black hypertensives. [10] [11] [12] [13] [14] Large clinical trials exploring demographic interactions and pharmacodynamics of anti-hypertensive medications in hypertensives of African-American descent have not been performed. The purpose of this manuscript is to report for the first time the results of a large clinical trial in hypertensives of African-American descent specifically exploring trough BP. Reduction in BP did not correlate with trough plasma trandolaprilat concentration. Pre-treatment plasma renin activity was not a reliable indicator of antihypertensive response, as similar reductions in BP occurred even in patients with the lowest renin levels. There were no observable differences based on age, gender or measurements of the renin-angiotensinaldosterone axis. In conclusion, neither age, gender or plasma renin activity influenced anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans.
issues related to the influence of age, gender and pretreatment plasma renin activity on blood pressure (BP) response to the nonsulfhydryl angiotensinconverting enzyme (ACE) inhibitor trandolapril, [15] [16] [17] [18] as well as to establish the proper dose response. Additionally, we will describe the influence of drug concentration on anti-hypertensive activity and the influence of age and gender with regards to changes in the renin-angiotensin-aldosterone axis in response to ACE inhibition.
Patients and methods

Study design
This was a randomised, double-blind, parallelgroup, placebo-controlled study in which the trandolapril dose-response characteristics were evaluated in a population of African-American hypertensive patients. Patients who had been newly diagnosed with, or had previously been treated for mild-to-moderate hypertension discontinued all anti-hypertensive medications, and entered into a single-blind, placebo run-in period of 4 weeks.
Only patients of self-described African-American descent with mild-to-moderate hypertension (supine diastolic BP between 95 mm Hg and 114 mm Hg) during both of the final two consecutive weeks of the placebo run-in period were randomised to receive double-blind medication, including either placebo, 0.25, 0.5, 1, 2, 4, 8, 12, or 16 mg trandolapril once daily for 6 weeks.
Patient population
African-American patients could be enrolled if they were over 21 years of age and had non-labile, mildto-moderate hypertension. Patients were not enrolled if they had any other form of hypertension (eg, malignant or severe); had suffered a cerebrovascular accident, convulsion or hypertensive encephalopathy within the previous year; experienced a myocardial infarct within 3 months of the study or had a history of severe cardiac abnormalities (such as CHF, arrhythmias, conduction abnormalities or AV block); been treated with anti-hypertensive medication within 4 weeks or spironolactone within 6 weeks of starting double-blind treatment; had evidence of renal, hepatic, haematological or other metabolic abnormalities which could interfere with study drug absorption, metabolism or excretion; had a history of drug abuse or addiction. Patients were excluded if they needed concomitant medications such as antidepressants, antiarrhythmic drugs, monoamine oxidase inhibitors, nonsteroidal antiinflammatory drugs, digitalis, or major tranquilizers. All patients signed an Institutional Review Board approved informed consent.
Study procedures
Patients were monitored on a regular basis over the duration of the study. Patients were monitored on a weekly basis during the placebo run-in period and during the first 2 weeks of the double-blind treatment period. All subsequent monitoring was at 2-week intervals. Patients consumed their usual ad libitum dietary salt intake.
Blood pressure was measured and trandolapril was administered once daily between 8.00 am to 10.00 am throughout the study. At each visit, an interim physical examination was done, vital signs and BP were measured, compliance was evaluated, and adverse experiences recorded. Special laboratory tests including ACE activity, serum aldosterone levels and plasma renin activity, were measured at baseline and after 6 weeks of double-blind treatment. Blood samples for these special tests were obtained in the recumbent position after the patient was supine for 30-45 min. During the double-blind period, BPs were measured at 'trough', just prior to study drug dosing, and approximately 4 -5 h after administration which coincides with peak plasma trandolaprilat concentrations and peak effect. 17 Blood samples were also taken during double-blind treatment to measure the trough and peak (4-5 h after dosing) plasma levels of trandolapril and trandolaprilat.
After 10 min in a supine position, BP measurements were made using a standard mercury sphygmomanometer in the arm determined to have the highest BP readings at the screening visit. Systolic BP was recorded at Phase I of the Korotkoff sounds and diastolic BP at Phase V of the Korotkoff sounds.
The mean of three consecutive (2 min apart) BP measurements were recorded.
Methodology for assays of renin, aldosterone, ACE activity, trandolapril, trandolaprilat
Plasma renin activity determinations were based on competitive binding principles of radio-immunoassay as previously described. 19 Serum aldosterone determinations were performed using radioimmunoassay procedures as described in Chattoraj et al. 20 The methodology for spectrophotometric determination of serum ACE activity is as described in Lieberman et al. 21 All assays were performed by Smith Kline Beecham Clinical Laboratories (Van Nuys, CA, USA).
Plasma concentrations of trandolapril and its diacid metabolite, trandolaprilat were measured by radioimmunoassay. Study drug samples were analysed blindly by Analytical Solutions Inc (Sunnyvale, CA, USA).
Measures of clinical effectiveness
The change in supine diastolic and systolic BP from baseline to end-point was used as the measure of clinical effectiveness. End-point was defined as the end of the double-blind period or the last visit during which the patient received double-blind medication.
Premature termination
Patients were withdrawn from the study if supine diastolic BP rose above 114 mm Hg at any point during the study and remained elevated above 114 mm Hg at a follow-up visit within 48 to 72 h, or the physician investigator felt it was in the patient's best medical interest.
Statistical and analytical methods
An intent-to-treat analysis was performed using mean end-point values for supine diastolic and systolic BPs measured as a change from baseline. Baseline data were the values recorded after 4 weeks of placebo medication. Baseline values for the nine treatment groups were compared using a one-way ANOVA. Post-treatment differences between treatments were compared using the same test with baseline values as covariates. Graphical displays represent unadjusted means. Data are expressed as mean ± s.e.m.
Results
Demographics
Three-hundred and twenty-two patients with mildto-moderate hypertension were enrolled from 12 study sites. Approximately 80% of all patients had been previously treated (mean = 10.6 ± 5.1 years) for hypertension.
As depicted in Table 1 , in each of the nine treatment groups, there were similar age, weight, pre- treatment diastolic and systolic BP and similar balance of gender, with the exception of the 1.0 mg trandolapril group which had seven males and 16 females. Thirty-two patients (12.2%) receiving trandolapril discontinued before the completion of the study, as did 12 patients (20%) on placebo treatment. In the intent-to-treat analysis, all discontinued patients were included except one patient in the 12 mg group who had no efficacy data reported.
Efficacy
After 6 weeks of therapy, trandolapril lowered diastolic and systolic BP significantly with the 2 mg dose ( Table 2) . Beyond the 4 mg dose there was no further reduction in either diastolic or systolic BP. The placebo effect was −0.7 ± 7.0 mm Hg. Although the number of patients is small, reduction in diastolic BP with trandolapril treatment were not markedly influenced by patient gender or age. Males started to have significant diastolic BP reduction at the 2 mg dose whereas females started at the 4 mg dose. Above 4 mg there was no further BP reduction in either group. While patients over age 65 years only comprised 19% of the patient's receiving trandolapril, Table 2 illustrates that there were no important differences in antihypertensive responses between younger and older patients. A plateauing of response rate occurred above 4 mg trandolapril.
There was not a correlation with pretreatment plasma renin activity and BP reduction in AfricanAmerican hypertensives when examining the data for all the doses together (r = −0.23) or specifically for equipotent doses of drug (doses 4 -16 mg QD) for lowering BP (Figure 1 ). For all patients, the mean baseline plasma renin activity before treatment was 0.7 ng/ml/hr increasing significantly (P Ͻ 0.01) to 2.1 ng/ml/hr after trandolapril treatment. The majority of patients either had low renin levels (n = 179) or normal renin levels (n = 57) with only a minority having high plasma renin activity (n = 18).
ACE activity, plasma renin activity, aldosterone values
Analysis of BP response was also performed by plasma renin category: low, normal or high in those patients who received equipotent doses of trandolapril for lowering BP (4 -16 mg QD). Urinary sodium excretions were not measured in these patients. Since plasma renin activities should be categorised relative to 24-h sodium excretion, the assignment of low, normal, and high renin was made using a nomogram which defines normal as a band that included 95% of the renin-sodium values of 104 normal subjects, and assumes that the hypertensive patients in these studies were not consuming (and excreting) large amounts of sodium. 21 A plasma renin activity below 0.7 ng angiotensin I/mL/hr was selected for low renin and above 3.0 ng angiotensin I/mL/hr for high renin. Serum ACE activity was measured at baseline and end-point in all patients. Trandolapril significantly reduced serum ACE activity with all doses evaluated (0.25-16 mg). The percent reduction from baseline ranged from 75.8 to 9.10% without significant difference in level of reduction for each dose. There was a statistically significant, and moderately strong negative correlation between percent ACE activity remaining (r = −0.38, P Ͻ 0.01) and plasma trandolaprilat concentration. As depicted in Table 3 , one notes a similar trandolapril-induced reduction in serum ACE irrespective of gender or age when examining equipotent anti-hypertensive doses of trandolapril (4 -16 mg QD).
Trandolapril therapy also resulted in a significant decline in plasma aldosterone in both males and Ϫ6.0 ± 0.6** Ϫ5.8 ± 0.9** Ϫ6.1 ± 0.8** Ϫ5.9 ± 0.6** Ϫ6.4 ± 1.5** ACE-Baseline (U/L) 145 32.3 ± 2.1 68 29.7 ± 2.0 77 34.6 ± 3.5 113 33.6 ± 2.6 32 27.8 ± 2.3 ACE-Change (U/L) Ϫ28.3 ± 2.1** Ϫ25.7 ± 1.9** Ϫ30.6 ± 3.5** Ϫ29.8 ± 2.5** Ϫ22.9 ± 2.3** Aldosterone-Baseline (ng/dL) 148 9.1 ± 0.5 69 8.7 ± 0.6 79 9.5 ± 0.7 115 9.6 ± 0.6 33 74 ± 0.6 Aldosterone-Change (ng/dL) Ϫ1.5 ± 0.5** Ϫ1.4 ± 0.6* Ϫ1.6 ± 0.7* Ϫ1.8 ± 0.6** Ϫ0.5 ± 0.6 Renin-Baseline (ng/mL/hr) 147 0.7 ± 0.1 68 0.7 ± 0.1 79 0.7 ± 0.1 114 0.8 ± 0.1 33 0.4 ± 0.1 Renin-Change (ng/mL/hr) 1.8 ± 0.6** 1.6 ± 0.5** 2.0 ± 0.9* 2.1 ± 0.7** 0.7 ± 0.3* Mean ± s.e. is shown for patients with data at the 4, 8, 12 or 16 mg trandolapril doses. *P Ͻ 0.05 change from baseline. **P Ͻ 0.01 change from baseline.
females and in patients Ͻ65 years of age (Table 3) . Although there was a similar reduction in aldosterone in patients у65, it did not achieve statistical significance. Increases in plasma renin activity in response to trandolapril therapy was similar in both men and women and in patients Ͻ65 (Table 3) . Although there was a significant increase in plasma renin activity in patients у65, the increase was of lesser magnitude than in patients Ͻ65.
Adverse events
Safety and tolerability was evaluated in all patients receiving the study drug. The most common adverse events reported (not necessarily drug related) were upper respiratory tract infection n = 13 (5.0%), cough n = 10 (3.8%), headache n = 10 (3.8%), oedema n = 7 (2.7%), upper respiratory tract congestion n = 6 (2.3%) and fatigue n = 4 (1.5%). There were no significant differences between any of the trandolapril treatment groups and placebo in the proportion of patients having adverse reactions. Adverse events necessitating withdrawal from the study occurred in eight patients (3.1%) randomised to trandolapril and three patients (5.0%) randomised to placebo.
Discussion
No large clinical trials have explored the demographic interactions and pharmacodynamics of ACE inhibitors in hypertensives of African-American descent. In this study, we evaluated a 64-fold dosing range of the ACE inhibitor trandolapril in 322 African-American hypertensive patients to explore the influence of age, gender, and pretreatment plasma renin activity on BP responses. Doses of 4 mg QD or greater provided similar levels of diastolic BP reduction. We did not observe any significant difference of any of these demographic interactions on subsequent BP reduction with equipotent anti-hypertensive doses of trandolapril (4-16 mg QD). Interestingly, pretreatment plasma renin activity did not predict BP responses with trandolapril treatment. Low plasma renin activity in hypertensive African-Americans has been suggested as a reason for the diminished efficacy of ACE inhibitors this group compared to Caucasians. However, our observations in a group of predominately low renin African-American hypertensives does not support this contention. In largely Caucasian populations, renin profiling is helpful in predicting acute BP responses. 22 However, with chronic ACE inhibitor treatment, the relationship between BP reduction and pre-treatment plasma renin levels diminishes. 23, 24 Thus race does not appear to alter this relationship. However, our data regarding renin profiling needs to be viewed carefully since we did not use any provocative or suppressive manoeuvers to alter renin responses. We used only a single determination on an ad libitum salt diet in the supine position which would tend to lead to suppressed levels. A more accurate, yet more difficult to perform assessment of plasma renin activity would be serial measurements throughout the day during varied postures and salt intake. This would provide a more accurate 24-h peripheral renin activity exposure. However, this effort would be impractical in a large scale clinical trial.
Trandolapril significantly inhibited serum ACE activity even with the lowest dose tested (0.25 mg). There was a statistically significant but weak negative correlation of end-point ACE activity, change in ACE activity from baseline to end-point, and plasma trandolaprilat concentration. There was also a moderately strong negative correlation between percent ACE activity remaining and plasma trandolaprilat concentration. However, there was no overall correlation between inhibition of ACE activity or trough plasma trandolaprilat concentration and BP reduction. These observations suggest that the antihypertensive activity of trandolapril is dependent upon other mechanisms in addition to blocking serum ACE. Other studies have suggested ACE inhibitors may reduce BP through augmenting vasodilatory prostaglandin production. 25 However, studies in indomethacin-pretreated spontaneously hypertensive rats suggest that prostaglandins are not involved in the anti-hypertensive response to trandolapril. 26 A similar lack of a prostaglandin mechanism has been suggested for captopril. 27 Trandolapril may also function through inhibiting the breakdown of vasodilatory kinins.
As with other ACE inhibitors, trandolapril therapy consistently reduced plasma aldosterone concentrations. 28 This effect may, in part, explain some of the anti-hypertensive properties of the drug since, in a largely low renin, salt sensitive population such as African-Americans, aldosterone, a hormone which amplifies renal salt conservation, may play a critical role in the genesis of volume expansion and hypertension. Further clinical trials will need to explore the clinical significance of this observation.
In summary, our results provide data concerning the optimal dose response of trandolapril in African-Americans. We also demonstrate that neither age, gender nor pre-treatment plasma renin activity predicts anti-hypertensive response to ACE inhibition in African-Americans when evaluating equipotent anti-hypertensive doses. The lack of correlation between BP reduction and inhibition of serum ACE activity or trough trandolapril concentration was interesting and suggests that other mechanisms may be operative.
